Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study.
Front Oncol
; 13: 1280416, 2023.
Article
in En
| MEDLINE
| ID: mdl-38023235
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Front Oncol
Year:
2023
Document type:
Article
Affiliation country:
Italy
Country of publication:
Switzerland